Pulmonary Function Testing (PFT) is an indispensable tool in the diagnosis, monitoring, and management of respiratory diseases. However, the complexity of the test often poses interpretative challenges for healthcare professionals. This article aims to demystify the intricacies of PFT interpretation.
The primary components of PFT include spirometry, lung volumes, and diffusion capacity. Spirometry measures the flow and volume of air that can be inhaled or exhaled, providing key insights into obstructive or restrictive lung diseases. Lung volumes help evaluate the extent of air trapping, while diffusion capacity assesses the gas exchange at the alveolar-capillary level.
Spirometry results are interpreted based on the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC). A reduced FEV1/FVC ratio indicates obstructive lung disease, while a normal or increased ratio with reduced volumes suggests restrictive lung disease.
Increased lung volumes, particularly residual volume, suggest air trapping common in obstructive diseases. Reduced diffusion capacity, on the other hand, may indicate interstitial lung disease, pulmonary vascular disease, or emphysema.
Interpreting PFTs requires a comprehensive approach, integrating findings from all components. For instance, a reduced FEV1/FVC ratio, increased lung volumes, and reduced diffusion capacity may suggest an obstructive disease with emphysema.
Understanding the nuances of PFT interpretation is critical for accurate diagnosis and management of respiratory diseases. While complex, a systematic approach to interpretation can help healthcare professionals effectively utilize this valuable tool. Continued education and practice are key to mastering PFT interpretation.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation